U.S. Markets open in 5 hrs 47 mins

Gilead Sciences May Witness Significant Drop in Revenues in 2018

Margaret Patrick
Gilead Sciences May Witness Significant Drop in Revenues in 2018

Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...